(VIANEWS) – Corcept Therapeutics Incorporated (CORT), Enova International (ENVA), Esquire Financial Holdings (ESQ) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Corcept Therapeutics Incorporated (CORT)
21.6% sales growth and 19.55% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.8.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 32.39. Meaning, the purchaser of the share is investing $32.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Corcept Therapeutics Incorporated’s EBITDA is 5.15.
2. Enova International (ENVA)
20.8% sales growth and 15.89% return on equity
Enova International, Inc., a technology and analytics company, provides online financial services in the United States, Brazil, Australia, and Canada. The company offers installment loans; line of credit accounts; receivables purchase agreements; CSO programs, including arranging loans with independent third-party lenders and assisting in the preparation of loan applications and loan documents; and bank programs, such as marketing services and loan servicing for near-prime unsecured consumer installment loan. It markets its financing products under the CashNetUSA, NetCredit, OnDeck, Headway Capital, The Business Backer, Simplic, and Pangea names. Enova International, Inc. was incorporated in 2011 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Enova International has a trailing twelve months EPS of $5.9.
PE Ratio
Enova International has a trailing twelve months price to earnings ratio of 7.07. Meaning, the purchaser of the share is investing $7.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.89%.
3. Esquire Financial Holdings (ESQ)
15.4% sales growth and 24.09% return on equity
Esquire Financial Holdings, Inc. operates as the bank holding company for Esquire Bank, National Association that provides commercial banking products and services to legal industry and small businesses, and commercial and retail customers in the United States. The company offers checking, savings, money market, and time deposits, as well as certificates of deposit. It also provides commercial loans, including short-term financing for inventory, receivables, the purchase of supplies, or other operating needs arising during the normal course of business, as well as loans to its qualified merchant customers; commercial lines of credit; consumer loans consisting of post-settlement consumer and structured settlement loans to plaintiffs and claimants, as well as loans to individuals for debt consolidation, medical expenses, living expenses, payment of outstanding bills, or other consumer needs; and real estate loans, such as multifamily, 1-4 family residential, commercial real estate, and construction loans, as well as merchant services. As of December 31, 2020, the company operated a full-service branch in Jericho, New York; and an administrative office in Boca Raton, Florida. Esquire Financial Holdings, Inc. was founded in 2006 and is headquartered in Jericho, New York.
Earnings Per Share
As for profitability, Esquire Financial Holdings has a trailing twelve months EPS of $4.86.
PE Ratio
Esquire Financial Holdings has a trailing twelve months price to earnings ratio of 9.6. Meaning, the purchaser of the share is investing $9.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.09%.
4. Boston Scientific (BSX)
7.8% sales growth and 6.68% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.82.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 67.79. Meaning, the purchaser of the share is investing $67.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
5. MYR Group (MYRG)
7.1% sales growth and 15.76% return on equity
MYR Group Inc., through its subsidiaries, provides electrical construction services in the United States and Canada. It operates through two segments, Transmission and Distribution, and Commercial and Industrial. The company's Transmission and Distribution segment offers a range of services on electric transmission and distribution networks, and substation facilities, including design, engineering, procurement, construction, upgrade, maintenance, and repair services with primary focus on construction, maintenance, and repair to customers in the electric utility industry. Its services include construction and maintenance of high voltage transmission lines, substations, and lower voltage underground and overhead distribution systems, and renewable power facilities; and limited gas construction services, as well as emergency restoration services in response to hurricane, ice, or other storm related damages. This segment serves as a prime contractor to customers, such as investor-owned utilities, cooperatives, private developers, government-funded utilities, independent power producers, independent transmission companies, industrial facility owners, and other contractors. Its Commercial and Industrial segment provides services, such as design, installation, maintenance, and repair of commercial and industrial wiring; and installation of traffic networks, bridge, roadway, and tunnel lighting. This segment offers its services for airports, hospitals, data centers, hotels, stadiums, convention centers, renewable energy projects, manufacturing plants, processing facilities, waste-water treatment facilities, mining facilities, and transportation control and management systems. It serves general contractors, commercial and industrial facility owners, governmental agencies, and developers. MYR Group Inc. was founded in 1891 and is headquartered in Henderson, Colorado.
Earnings Per Share
As for profitability, MYR Group has a trailing twelve months EPS of $5.44.
PE Ratio
MYR Group has a trailing twelve months price to earnings ratio of 22.41. Meaning, the purchaser of the share is investing $22.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.76%.
Volume
Today’s last reported volume for MYR Group is 57742 which is 53.32% below its average volume of 123709.
Yearly Top and Bottom Value
MYR Group’s stock is valued at $121.89 at 19:22 EST, way below its 52-week high of $156.63 and way above its 52-week low of $84.75.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.5%, now sitting on 3.5B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MYR Group’s EBITDA is 0.6.
6. Employers Holdings (EIG)
5.9% sales growth and 13.01% return on equity
Employers Holdings, Inc., through its subsidiaries, operates in the commercial property and casualty insurance industry primarily in the United States. It offers workers' compensation insurance to small businesses in low to medium hazard industries. The company markets its products through independent local, regional, and national agents and brokers; alternative distribution channels; and national, regional, and local trade groups and associations, as well as directly to customers. Employers Holdings, Inc. was founded in 2000 and is based in Reno, Nevada.
Earnings Per Share
As for profitability, Employers Holdings has a trailing twelve months EPS of $4.41.
PE Ratio
Employers Holdings has a trailing twelve months price to earnings ratio of 8.64. Meaning, the purchaser of the share is investing $8.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.01%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.4%, now sitting on 847M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 13.6% and positive 1.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 6, 2023, the estimated forward annual dividend rate is 1.12 and the estimated forward annual dividend yield is 3%.
Previous days news about Employers Holdings(EIG)
- According to Zacks on Thursday, 23 November, "While Assurant sports a Zacks Rank #1 (Strong Buy) now, Brown & Brown and Employers Holdings carry a Zacks Rank #2 each. "
- According to Zacks on Thursday, 23 November, "Some better-ranked stocks from the insurance industry are Aflac Incorporated (AFL Quick QuoteAFL – Free Report) , Employers Holdings Inc. (EIG Quick QuoteEIG – Free Report) and Kinsale Capital Group, Inc. (KNSL Quick QuoteKNSL – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. "
